Higher doses of vitamin D help prevent falls, study finds

Share this article:
Seniors aged 65 and older can significantly reduce their risk of falls by taking vitamin D supplements every day. But they need to take more of the vitamin than previously thought, according to the results of a new study.

Currently, the U.S. Institutes of Medicine recommend adults aged 51 to 70 take 400 International Units (IU) of vitamin D each day, and seniors aged 71 and older take 600 IU per day. After taking a close look at eight studies concerning the relationship between vitamin D and falls, researchers at the University of Zurich, Switzerland, concluded that those doses aren't enough. Vitamin D supplements of between 700 and 1,000 IU taken daily are associated with at least a 19% reduction in the risk of falls, they discovered. Vitamin D3 proved even more potent, reducing the risk of falls by 26%. Doses of less than 700 IU do not provide significant benefits when it came to falls prevention, researchers say. Falls are the most common reason seniors may need nursing home or rehabilitative care.

The effects of the higher doses of vitamin D become apparent after just a few months, and the benefits typically last for years, according to the researchers. The report was published online in the Oct. 2 edition of the British Medical Journal.

Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.